14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SAX vs HCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over SAX (SAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SAX carries a Unified Composite Score of 52.0/100 (HOLD) at $24.43 (N/M Forward P/E, N/A operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin).
Composite vs. Pillar Nuance: While SAX currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. HCM 38.1/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. N/A operating margin) and revenue trajectory (+0.2% vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SAX vs HCM. Trailing 12-month operating profitability (SAX N/A vs HCM -6.3%) and valuation multiples (SAX N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment19.6% of Rev ($108M)
90D Engineering Disclosures0 Published
Investor FAQ SAX vs HCM Key Questions & Quantitative Answers
As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over SAX (SAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SAX carries a Unified Composite Score of 52.0/100 (HOLD) at $24.43 (N/M Forward P/E, N/A operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin). Composite vs. Pillar Nuance: While SAX currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. HCM 38.1/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. N/A operating margin) and revenue trajectory (+0.2% vs. N/A YoY).
HCM leads the Growth & Scale pillar: SAX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, SAX generates N/A in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, SAX deploys N/A (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.
HCM screens cheaper on headline valuation multiples. SAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SAX (N/A ROE) versus HCM (1.5% ROE) capital efficiency.
In options market volatility and institutional positioning, SAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 8% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.